Appendix 4c quarterly activity report for quarter ended december 31, 2024

New york, jan. 30, 2025 (globe newswire) -- mesoblast limited (nasdaq:meso; asx:msb), global leader in allogeneic cellular medicines for inflammatory diseases, today provided highlights of its recent activities for the second quarter ended december 31, 2024.

MESO Ratings Summary

MESO Quant Ranking